ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE
Clinical trials for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE explained in plain language.
Never miss a new study
Get alerted when new ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE trials appear
Sign up with your email to follow new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Supercharged donor cells take on stubborn lymphomas
Disease control Recruiting nowThis early-stage study tests a new type of cell therapy for people with certain lymphomas that have come back or not responded to treatment. The therapy uses immune cells from healthy donors that are modified to better recognize and attack cancer cells, plus an added molecule to …
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated May 17, 2026 03:17 UTC
-
New hope for kids with rare ALK+ cancers: brigatinib trial opens
Disease control Recruiting nowThis study tests a drug called brigatinib in children and young adults (ages 1 to 25) with ALK-positive cancers, including anaplastic large cell lymphoma and inflammatory myofibroblastic tumors. The goal is to find the best dose and see how safe and effective the drug is. About 6…
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE
Phase: PHASE1, PHASE2 • Sponsor: Princess Maxima Center for Pediatric Oncology • Aim: Disease control
Last updated May 15, 2026 11:56 UTC